β-thalassemia is a blood disorder that limits the body's ability to produce beta-globin, a protein needed for red blood cells and hemoglobin. It's caused by a mutation in the beta globin gene, which results in an imbalance of alpha and beta globin. This imbalance leads to anemia and other medical issues.

CRISPR is a gene editing technology that allows researchers to modify the DNA of living organisms. It's an acronym for "clustered regularly interspaced short palindromic repeats".

Recently UK first to approve CRISPR treatment for these two diseases. The landmark decision could transform the treatment of sickle-cell disease and β-thalassaemia — but the technology is expensive.

CRISPR technology has been applied in clinical treatment research for β-thalassemia and has shown great potential.

Ongoing clinical trials are evaluating the safety and efficacy of CRISPR-Cas9 technology in treating patients with transfusion-dependent β-thalassemia. For example, a multicenter, open-label phase 1 study is assessing the safety and efficacy of a single dose of autologous CRISPR-Cas9-modified CD34+ human hematopoietic stem and progenitor cells (hHSPCs).

Here is also research exploring the use of CRISPR-Cas9 technology to knock out the BCL11A gene to reactivate fetal hemoglobin, as a promising method for treating β-thalassemia.

In summary, CRISPR technology has shown great potential in the treatment of β-thalassemia, and ongoing clinical trials and research are further exploring its application in this field.